January 2020 is the third anniversary of the implementation of
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in
Expert: Keep up with latest discoveries through automated updates in reporting genetic test results
Maybe the genetic test report your doctor ordered says your